In heart failure patients, loss of kidney function is a good predictor of longer hospital stays and mortality. Marketed heart failure medications - diuretics and vasodilators - often cause renal damage, thereby complicating their use and, in severe cases, confounding their therapeutic benefit. NovaCardia Inc. believes that its KW-3902 diuretic will protect or even improve renal function. In addition, given its mechanism, it should be synergistic with marketed diuretics.
This week, NovaCardia (San Diego, Calif.) was to report data from three U.S. Phase II trials (CKI-201, CKI-202 and